SK4692003A3 - Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same - Google Patents

Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same Download PDF

Info

Publication number: SK4692003A3
Authority: SK; Slovakia
Prior art keywords: formula; group; compound; compounds; pharmaceutically acceptable
Prior art date: 2000-09-15

Application number

SK469-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Carole Descamps-Francois

Said Yous

Daniel Lesieur

Gerald Guillaumet

Marie-Claude Viaud

Costa Herve Da

Caroline Bennejean

Philippe Delagrange

Pierre Renard

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2001-07-16

Publication date

2003-08-05

2001-07-16 Application filed by Servier Lab filed Critical Servier Lab

2003-08-05 Publication of SK4692003A3 publication Critical patent/SK4692003A3/sk

Links

238000000034 method Methods 0.000 title claims description 50
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 143
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims description 58
-1 morpholinyl- Chemical group 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 21
239000002253 acid Substances 0.000 claims description 20
125000000217 alkyl group Chemical group 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 12
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
230000001193 melatoninergic effect Effects 0.000 claims description 9
125000005843 halogen group Chemical group 0.000 claims description 8
125000005842 heteroatom Chemical group 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
239000001301 oxygen Substances 0.000 claims description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
VTMXSWVEWDJSKG-UHFFFAOYSA-N 4-[4-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 VTMXSWVEWDJSKG-UHFFFAOYSA-N 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
239000011593 sulfur Chemical group 0.000 claims description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
239000000460 chlorine Substances 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
239000007858 starting material Substances 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
239000002841 Lewis acid Substances 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000002619 bicyclic group Chemical group 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
230000007062 hydrolysis Effects 0.000 claims description 2
238000006460 hydrolysis reaction Methods 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
150000007517 lewis acids Chemical class 0.000 claims description 2
POTVIPHGYAOPMA-UHFFFAOYSA-N methyl 4-[4-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCCCOC1=CC=C(C=CC=C2CCNC(C)=O)C2=C1 POTVIPHGYAOPMA-UHFFFAOYSA-N 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
SOUJSQWCVACZMI-UHFFFAOYSA-N n-[2-[7-[4-(3-phenylphenoxy)butoxy]naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCCCOC(C=1)=CC=CC=1C1=CC=CC=C1 SOUJSQWCVACZMI-UHFFFAOYSA-N 0.000 claims description 2
YQYBXNHHZVVUME-UHFFFAOYSA-N n-[2-[7-[4-(4-phenylphenoxy)butoxy]naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCCCOC(C=C1)=CC=C1C1=CC=CC=C1 YQYBXNHHZVVUME-UHFFFAOYSA-N 0.000 claims description 2
239000012038 nucleophile Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
238000007670 refining Methods 0.000 claims description 2
150000003573 thiols Chemical class 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 1
229910002056 binary alloy Inorganic materials 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
VDBKGGONHKGNTE-UHFFFAOYSA-N n-[2-[7-[4-[4-[4-(hydroxymethyl)phenyl]phenoxy]butoxy]naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCCCOC(C=C1)=CC=C1C1=CC=C(CO)C=C1 VDBKGGONHKGNTE-UHFFFAOYSA-N 0.000 claims 1
125000002947 alkylene group Chemical group 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
239000004305 biphenyl Substances 0.000 description 18
239000000243 solution Substances 0.000 description 17
230000000694 effects Effects 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 13
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
229910052943 magnesium sulfate Inorganic materials 0.000 description 10
235000019341 magnesium sulphate Nutrition 0.000 description 10
239000007787 solid Substances 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
102000001419 Melatonin receptor Human genes 0.000 description 9
108050009605 Melatonin receptor Proteins 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
238000003756 stirring Methods 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000027455 binding Effects 0.000 description 8
229910052739 hydrogen Inorganic materials 0.000 description 8
230000033764 rhythmic process Effects 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
238000004452 microanalysis Methods 0.000 description 7
238000010992 reflux Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
235000010290 biphenyl Nutrition 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000027288 circadian rhythm Effects 0.000 description 5
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
239000003446 ligand Substances 0.000 description 5
229960003987 melatonin Drugs 0.000 description 5
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241001494479 Pecora Species 0.000 description 4
238000001816 cooling Methods 0.000 description 4
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
PHBQSOODLMGROT-UHFFFAOYSA-N methyl 4-(4-hydroxyphenyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CC=C(O)C=C1 PHBQSOODLMGROT-UHFFFAOYSA-N 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
230000007170 pathology Effects 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
208000019116 sleep disease Diseases 0.000 description 4
YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 4
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
208000019454 Feeding and Eating disease Diseases 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
230000000949 anxiolytic effect Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
230000006742 locomotor activity Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
229960001802 phenylephrine Drugs 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
235000011181 potassium carbonates Nutrition 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
208000012672 seasonal affective disease Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
ITKOVDPTEKNQEL-UHFFFAOYSA-N 4-[4-(hydroxymethyl)phenyl]phenol Chemical compound C1=CC(CO)=CC=C1C1=CC=C(O)C=C1 ITKOVDPTEKNQEL-UHFFFAOYSA-N 0.000 description 2
208000027559 Appetite disease Diseases 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000002060 circadian Effects 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000007704 transition Effects 0.000 description 2
XLUAOPYZCRBSPN-UHFFFAOYSA-N 1,1'-biphenyl;1h-indole Chemical group C1=CC=C2NC=CC2=C1.C1=CC=CC=C1C1=CC=CC=C1 XLUAOPYZCRBSPN-UHFFFAOYSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical group BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
AGYSXPVGOQBEKA-UHFFFAOYSA-N 1h-benzimidazole;1,1'-biphenyl Chemical group C1=CC=C2NC=NC2=C1.C1=CC=CC=C1C1=CC=CC=C1 AGYSXPVGOQBEKA-UHFFFAOYSA-N 0.000 description 1
XUGDRCVJICJDBW-UHFFFAOYSA-N 3-[3-[4-[[8-(2-acetamidoethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]butoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)CCCC2=CC=C1OCCCCOC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XUGDRCVJICJDBW-UHFFFAOYSA-N 0.000 description 1
OHQWQSSYYKZKOJ-UHFFFAOYSA-N 3-ethoxy-4-phenylbenzoic acid Chemical compound CCOC1=CC(C(O)=O)=CC=C1C1=CC=CC=C1 OHQWQSSYYKZKOJ-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
RBHMMRHZYYAJAW-UHFFFAOYSA-N 4-(2-ethylphenyl)phenol Chemical compound CCC1=CC=CC=C1C1=CC=C(O)C=C1 RBHMMRHZYYAJAW-UHFFFAOYSA-N 0.000 description 1
VUFLBMQPNHUFQK-UHFFFAOYSA-N 4-[4-[2-[8-(2-acetamidoethyl)naphthalen-2-yl]oxyethoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 VUFLBMQPNHUFQK-UHFFFAOYSA-N 0.000 description 1
XJKCCGBFKBJKBJ-UHFFFAOYSA-N 4-[4-[2-[[3-(2-acetamidoethyl)-1h-indol-5-yl]oxy]ethoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=CNC2=CC=C1OCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 XJKCCGBFKBJKBJ-UHFFFAOYSA-N 0.000 description 1
QJBPQCYRUJTKLT-UHFFFAOYSA-N 4-[4-[3-[8-[2-[(2,2,2-trifluoroacetyl)amino]ethyl]naphthalen-2-yl]oxypropoxy]phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1OCCCOC1=CC=C(C=CC=C2CCNC(=O)C(F)(F)F)C2=C1 QJBPQCYRUJTKLT-UHFFFAOYSA-N 0.000 description 1
GGGCVHLNEBLUDF-UHFFFAOYSA-N 4-[4-[4-[[3-(2-acetamidoethyl)-1-benzofuran-5-yl]oxy]butoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=COC2=CC=C1OCCCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 GGGCVHLNEBLUDF-UHFFFAOYSA-N 0.000 description 1
VVYGPIQNAMXCJG-UHFFFAOYSA-N 4-[4-[4-[[3-(2-acetamidoethyl)-1-benzothiophen-5-yl]oxy]butoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=CSC2=CC=C1OCCCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 VVYGPIQNAMXCJG-UHFFFAOYSA-N 0.000 description 1
WVZFSGVMMCPUEV-UHFFFAOYSA-N 4-[4-[4-[[3-(2-acetamidoethyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]oxy]butoxy]phenyl]benzoic acid Chemical compound C1=C2C(CCNC(=O)C)=CNC2=NC=C1OCCCCOC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 WVZFSGVMMCPUEV-UHFFFAOYSA-N 0.000 description 1
OKKZRRSTEKRRQN-UHFFFAOYSA-N 4-phenylbenzenecarboperoxoic acid Chemical compound C1=CC(C(=O)OO)=CC=C1C1=CC=CC=C1 OKKZRRSTEKRRQN-UHFFFAOYSA-N 0.000 description 1
NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
CKLTZKQATVYDLR-UHFFFAOYSA-N C(C)(=O)C1(C=CC2=NC=C(CCN)C2=C1)OC Chemical compound C(C)(=O)C1(C=CC2=NC=C(CCN)C2=C1)OC CKLTZKQATVYDLR-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
208000017164 Chronobiology disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033664 Panic attack Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical compound OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000008632 circadian clock Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000002366 halogen compounds Chemical class 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
CTLLOVGEFLEJEI-UHFFFAOYSA-N methyl 4-[4-[2-[8-(2-acetamidoethyl)naphthalen-2-yl]oxyethoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCOC1=CC=C(C=CC=C2CCNC(C)=O)C2=C1 CTLLOVGEFLEJEI-UHFFFAOYSA-N 0.000 description 1
MOHHRIBQMWPGER-UHFFFAOYSA-N methyl 4-[4-[2-[8-[2-(butanoylamino)ethyl]naphthalen-2-yl]oxyethoxy]phenyl]benzoate Chemical compound C1=C2C(CCNC(=O)CCC)=CC=CC2=CC=C1OCCOC(C=C1)=CC=C1C1=CC=C(C(=O)OC)C=C1 MOHHRIBQMWPGER-UHFFFAOYSA-N 0.000 description 1
YPGHQAQUFDMOFF-UHFFFAOYSA-N methyl 4-[4-[2-[[3-[2-(furan-2-carbonylamino)ethyl]-1-benzofuran-5-yl]oxy]ethoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCOC1=CC=C(OC=C2CCNC(=O)C=3OC=CC=3)C2=C1 YPGHQAQUFDMOFF-UHFFFAOYSA-N 0.000 description 1
LJSGUGZJFQFGIM-UHFFFAOYSA-N methyl 4-[4-[3-[8-(2-acetamidoethyl)naphthalen-2-yl]oxypropoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCCOC1=CC=C(C=CC=C2CCNC(C)=O)C2=C1 LJSGUGZJFQFGIM-UHFFFAOYSA-N 0.000 description 1
LPFXSKUACCTRFL-UHFFFAOYSA-N methyl 4-[4-[3-[8-[2-[(2,2,2-trifluoroacetyl)amino]ethyl]naphthalen-2-yl]oxypropoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCCOC1=CC=C(C=CC=C2CCNC(=O)C(F)(F)F)C2=C1 LPFXSKUACCTRFL-UHFFFAOYSA-N 0.000 description 1
CIDIKCBVSNXYSZ-UHFFFAOYSA-N methyl 4-[4-[4-[[3-(2-acetamidoethyl)-1-benzofuran-5-yl]sulfanyl]butoxy]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C=C1)=CC=C1OCCCCSC1=CC=C(OC=C2CCNC(C)=O)C2=C1 CIDIKCBVSNXYSZ-UHFFFAOYSA-N 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
SWFFADGCZNYXKT-UHFFFAOYSA-N n-[2-(5-amino-1-benzofuran-3-yl)ethyl]acetamide Chemical compound C1=C(N)C=C2C(CCNC(=O)C)=COC2=C1 SWFFADGCZNYXKT-UHFFFAOYSA-N 0.000 description 1
UIZKUOKUDYNNOL-UHFFFAOYSA-N n-[2-(5-bromo-1-benzofuran-3-yl)ethyl]acetamide Chemical compound C1=C(Br)C=C2C(CCNC(=O)C)=COC2=C1 UIZKUOKUDYNNOL-UHFFFAOYSA-N 0.000 description 1
NDDMXCWNHGZTGP-UHFFFAOYSA-N n-[2-(5-hydroxy-1-benzofuran-3-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=COC2=C1 NDDMXCWNHGZTGP-UHFFFAOYSA-N 0.000 description 1
JFTDJRMNQHUDOW-UHFFFAOYSA-N n-[2-(5-hydroxy-1-benzothiophen-3-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CSC2=C1 JFTDJRMNQHUDOW-UHFFFAOYSA-N 0.000 description 1
JVDJIRVQCCGUSA-UHFFFAOYSA-N n-[2-(5-hydroxy-1-methylpyrrolo[2,3-b]pyridin-3-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CN(C)C2=N1 JVDJIRVQCCGUSA-UHFFFAOYSA-N 0.000 description 1
TUEMQWRPQVKRDX-UHFFFAOYSA-N n-[2-(5-hydroxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(O)=CN=C2NC=C1CCNC(=O)C1CC1 TUEMQWRPQVKRDX-UHFFFAOYSA-N 0.000 description 1
WIZISPUPCYLOGO-UHFFFAOYSA-N n-[2-(5-iodo-1-benzofuran-3-yl)ethyl]acetamide Chemical compound C1=C(I)C=C2C(CCNC(=O)C)=COC2=C1 WIZISPUPCYLOGO-UHFFFAOYSA-N 0.000 description 1
YEGSZNJGJOBWNN-UHFFFAOYSA-N n-[2-(6-hydroxy-3h-inden-1-yl)ethyl]pentanamide Chemical compound C1=C(O)C=C2C(CCNC(=O)CCCC)=CCC2=C1 YEGSZNJGJOBWNN-UHFFFAOYSA-N 0.000 description 1
CHPCGRFPKVEFJJ-UHFFFAOYSA-N n-[2-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)CCCC2=C1 CHPCGRFPKVEFJJ-UHFFFAOYSA-N 0.000 description 1
UNTZQBYXDYYXIY-UHFFFAOYSA-N n-[2-(7-hydroxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CC=CC2=C1 UNTZQBYXDYYXIY-UHFFFAOYSA-N 0.000 description 1
QLEHDJFJSAUQRF-UHFFFAOYSA-N n-[2-(7-hydroxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C12=CC(O)=CC=C2C=CC=C1CCNC(=O)C1CCC1 QLEHDJFJSAUQRF-UHFFFAOYSA-N 0.000 description 1
NBKDXUHWNYSOFI-UHFFFAOYSA-N n-[2-[7-(2-bromoethoxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C(OCCBr)C=C2C(CCNC(=O)C)=CC=CC2=C1 NBKDXUHWNYSOFI-UHFFFAOYSA-N 0.000 description 1
GOTALDQWPXWRTQ-UHFFFAOYSA-N n-[2-[7-(4-bromobutoxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C(OCCCCBr)C=C2C(CCNC(=O)C)=CC=CC2=C1 GOTALDQWPXWRTQ-UHFFFAOYSA-N 0.000 description 1
APJPWWGKVARGDS-UHFFFAOYSA-N n-[2-[7-[2-[4-[4-(hydroxymethyl)phenyl]phenoxy]ethoxy]naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC=CC2=CC=C1OCCOC(C=C1)=CC=C1C1=CC=C(CO)C=C1 APJPWWGKVARGDS-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000005825 oxyethoxy group Chemical group [H]C([H])(O[*:1])C([H])([H])O[*:2] 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

SK469-2003A 2000-09-15 2001-07-16 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same SK4692003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0011779A FR2814165B1 (fr)	2000-09-15	2000-09-15	Nouveaux derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2001/002297 WO2002022555A1 (fr)	2000-09-15	2001-07-16	Derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
SK4692003A3 true SK4692003A3 (en)	2003-08-05

Family

ID=8854338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK469-2003A SK4692003A3 (en)	2000-09-15	2001-07-16	Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same

Country Status (23)

Country	Link
US (2)	US7161035B2 (de)
EP (1)	EP1317413B1 (de)
JP (1)	JP4015546B2 (de)
KR (1)	KR100580780B1 (de)
CN (1)	CN1233621C (de)
AT (1)	ATE302750T1 (de)
AU (2)	AU2001277595B2 (de)
BR (1)	BR0113907A (de)
CA (1)	CA2419934C (de)
DE (1)	DE60112951T2 (de)
DK (1)	DK1317413T3 (de)
EA (1)	EA005766B1 (de)
ES (1)	ES2248365T3 (de)
FR (1)	FR2814165B1 (de)
HU (1)	HUP0303349A3 (de)
MX (1)	MXPA03002018A (de)
NO (1)	NO20031043L (de)
NZ (1)	NZ524330A (de)
PL (1)	PL360574A1 (de)
PT (1)	PT1317413E (de)
SK (1)	SK4692003A3 (de)
WO (1)	WO2002022555A1 (de)
ZA (1)	ZA200301351B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007537296A (ja) *	2004-05-14	2007-12-20	アボット・ラボラトリーズ	治療薬としてのキナーゼ阻害薬
KR100626438B1 (ko) *	2005-02-24	2006-09-21	웅진코웨이주식회사	산소발생기용 배관 모듈
ES2694049T3 (es)	2014-01-14	2018-12-17	Astellas Pharma Inc.	Compuesto de indol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5093352A (en) *	1988-11-14	1992-03-03	Whitby Research, Inc.	Antidepressant agents
EP0848699B1 (de) *	1995-07-26	2001-10-24	Takeda Chemical Industries, Ltd.	Benzocycloalken-verbindungen mit bindungsaffinität an den melatonin-rezeptor, ihre herstellung und verwendung
US5808151A (en) *	1996-04-17	1998-09-15	Bristol-Myers Squibb Company	Biphenylamido derivatives as melatonergic agents
FR2771739B1 (fr) *	1997-11-28	2001-04-20	Adir	Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2772766B1 (fr) *	1997-12-24	2000-06-30	Adir	Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2778662B1 (fr) *	1998-05-12	2000-06-16	Adir	Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2784375B1 (fr) *	1998-10-12	2000-11-24	Adir	Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2000
- 2000-09-15 FR FR0011779A patent/FR2814165B1/fr not_active Expired - Fee Related
2001
- 2001-07-16 PT PT01955425T patent/PT1317413E/pt unknown
- 2001-07-16 WO PCT/FR2001/002297 patent/WO2002022555A1/fr not_active Ceased
- 2001-07-16 AU AU2001277595A patent/AU2001277595B2/en not_active Ceased
- 2001-07-16 EP EP01955425A patent/EP1317413B1/de not_active Expired - Lifetime
- 2001-07-16 US US10/380,866 patent/US7161035B2/en not_active Expired - Fee Related
- 2001-07-16 DE DE60112951T patent/DE60112951T2/de not_active Expired - Fee Related
- 2001-07-16 KR KR1020037003773A patent/KR100580780B1/ko not_active Expired - Fee Related
- 2001-07-16 PL PL36057401A patent/PL360574A1/xx unknown
- 2001-07-16 MX MXPA03002018A patent/MXPA03002018A/es active IP Right Grant
- 2001-07-16 CN CNB018156428A patent/CN1233621C/zh not_active Expired - Fee Related
- 2001-07-16 NZ NZ52433001A patent/NZ524330A/xx unknown
- 2001-07-16 AU AU7759501A patent/AU7759501A/xx active Pending
- 2001-07-16 AT AT01955425T patent/ATE302750T1/de not_active IP Right Cessation
- 2001-07-16 ES ES01955425T patent/ES2248365T3/es not_active Expired - Lifetime
- 2001-07-16 BR BR0113907-0A patent/BR0113907A/pt not_active IP Right Cessation
- 2001-07-16 DK DK01955425T patent/DK1317413T3/da active
- 2001-07-16 JP JP2002526756A patent/JP4015546B2/ja not_active Expired - Fee Related
- 2001-07-16 HU HU0303349A patent/HUP0303349A3/hu unknown
- 2001-07-16 EA EA200300376A patent/EA005766B1/ru not_active IP Right Cessation
- 2001-07-16 CA CA002419934A patent/CA2419934C/fr not_active Expired - Fee Related
- 2001-07-16 SK SK469-2003A patent/SK4692003A3/sk unknown
2003
- 2003-02-19 ZA ZA200301351A patent/ZA200301351B/en unknown
- 2003-03-06 NO NO20031043A patent/NO20031043L/no not_active Application Discontinuation
2006
- 2006-12-18 US US11/640,595 patent/US20070123529A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1317413B1 (de)	2005-08-24
KR100580780B1 (ko)	2006-05-22
PT1317413E (pt)	2005-11-30
KR20030059140A (ko)	2003-07-07
FR2814165B1 (fr)	2002-11-22
US20070123529A1 (en)	2007-05-31
HUP0303349A2 (hu)	2004-01-28
EA005766B1 (ru)	2005-06-30
AU7759501A (en)	2002-03-26
DE60112951T2 (de)	2006-06-14
BR0113907A (pt)	2003-07-22
US7161035B2 (en)	2007-01-09
NO20031043D0 (no)	2003-03-06
PL360574A1 (en)	2004-09-06
DK1317413T3 (da)	2005-11-21
HUP0303349A3 (en)	2005-02-28
AU2001277595B2 (en)	2006-08-17
ATE302750T1 (de)	2005-09-15
HK1058354A1 (en)	2004-05-14
EA200300376A1 (ru)	2003-08-28
EP1317413A1 (de)	2003-06-11
JP2004518627A (ja)	2004-06-24
CA2419934C (fr)	2008-01-15
FR2814165A1 (fr)	2002-03-22
ES2248365T3 (es)	2006-03-16
DE60112951D1 (de)	2005-09-29
CA2419934A1 (fr)	2003-03-21
US20040014969A1 (en)	2004-01-22
JP4015546B2 (ja)	2007-11-28
WO2002022555A1 (fr)	2002-03-21
CN1457337A (zh)	2003-11-19
NZ524330A (en)	2004-12-24
ZA200301351B (en)	2004-02-19
MXPA03002018A (es)	2003-07-24
CN1233621C (zh)	2005-12-28
NO20031043L (no)	2003-03-06

Publication	Publication Date	Title
ES2255261T3 (es)	2006-06-16	Nuevos compuestos ciclicos sustituidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AU766322B2 (en)	2003-10-16	New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them
AU704261B2 (en)	1999-04-15	Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them
US7462741B2 (en)	2008-12-09	Naphthalene compounds
JP4015546B2 (ja)	2007-11-28	置換ビフェニル誘導体、その製造方法およびそれを含有する医薬組成物
AU761605B2 (en)	2003-06-05	New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them
AU2007203040A1 (en)	2008-01-17	New naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them